Medicines

The Medicines Company was a biopharmaceutical firm dedicated to delivering innovative solutions for the treatment of critical cardiovascular diseases. The company's primary focus was the development of inclisiran, a first-in-class small interfering RNA (siRNA) therapy designed to lower LDL cholesterol by targeting the PCSK9 protein. Before its acquisition, the company successfully commercialized several acute care products, including Angiomax and Kengreal, which were widely used in hospital settings for anticoagulation during cardiac procedures. In early 2020, the company was acquired by Novartis for approximately $9.7 billion, primarily to secure inclisiran (now marketed as Leqvio) as a cornerstone of Novartis's cardiovascular portfolio.